News & Insights

Catch the recording of the first in our series of two events celebrating British innovation and new technologies held in conjunction with our friends at Rathbone Investment Management.

OIC portfolio company Cytox launches a non-invasive genetic test enabling physicians to assess an individual’s risk of cognitive decline due to Alzheimer’s from a simple saliva sample provided from home.

Excitingly, the test can guide lifestyle interventions to potentially slow disease progression.

We’re excited to announce the launch of the first 2021 round of the Oxford Technology and Innovations EIS Fund (OTIF) advised by us and managed by Thompson Taraz!

• SpyBiotech Ltd is developing a novel “plug and play” vaccine platform technology targeting infectious diseases, cancer and chronic diseases.
• OTIF’s investment was advised by Oxford Investment Consultants LLP and was part of a $32.5m round led by Braavos Investment Advisers.
• Lutz B. Giebel joins as Chair, strengthening governance as company expands clinical development and builds operational resource.

This holiday season is unlike any other, to finish off a year unlike any other we have known.

We’d like to take this opportunity to thank our companies, investors and co-investors for their patience and support in 2020.

Throughout this season and as we move into 2021, we wish you moments of peace amid the difficulties, and connections with your families and friends, even if they can’t be in person.

Best wishes

George, Ross, Christopher & James

– The OIC Partners